Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention ,
, World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, American Heart Association, vol.120, issue.16, pp.1640-1645, 2009.
Some biological correlates of drug resistance in schizophrenia: a multidimensional approach, World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry, vol.6, issue.2, pp.23-30, 2005. ,
Remission in schizophrenia: proposed criteria and rationale for consensus, Am. J. Psychiatry. mars, vol.162, issue.3, pp.441-450, 2005. ,
Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset, Schizophr. Bull. sept, vol.42, issue.5, pp.1290-302, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01482349
Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials, Aust. N. Z. J. Psychiatry. 13 mars, 2019. ,
The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance, Arch. Gen. Psychiatry. juin, vol.33, issue.6, pp.766-71, 1976. ,
What does plasma CRP tell us about peripheral and central inflammation in depression?, Mol. Psychiatry, vol.12, 2018. ,
C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications, Mol. Psychiatry. 14 juill, 2015. ,
,
,
, Prise de posture (maintien actif, contre la gravité, d'une posture adoptée spontanément)
,
, Stéréotypies (mouvements non dirigés vers un but, répétitifs et anormalement fréquents)
, Agitation, non influencée par des stimuli externes
, Expressions faciales grimaçantes
, l'absence d'élément clinique en faveur d'un trouble thymique (tristesse de l'humeur, anhédonie?) et de l'absence d'antécédent d'épisode maniaque
, Critères diagnostiques de trouble dépressif caractérisé (DSM-5)
, Présence d'au moins cinq sur les neuf symptômes suivants, présents pour une durée d'au moins deux semaines
, Diminution marquée de l
,
, Agitation ou ralentissement psychomoteur
, Fatigue ou perte d'énergie
, Pensées de mort récurrentes, idées suicidaires récurrentes sans plan précis ou tentative de suicide ou plan précis pour se suicider
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention ,
, American Heart Association; World Heart Federation
, International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation, vol.120, issue.16, pp.1640-1645, 2009.
, Rev. Mal. Respir. juin, vol.35, issue.6, pp.673-85, 2018.
Remission in schizophrenia: proposed criteria and rationale for consensus, Am. J. Psychiatry. mars, vol.162, issue.3, pp.441-450, 2005. ,
Validation of the Pediatric Catatonia Rating Scale (PCRS), Schizophr. Res. oct, vol.176, issue.2-3, pp.378-86, 2016. ,
C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events, Arterioscler. Thromb. Vasc. Biol, vol.22, issue.10, pp.1512-1515, 2002. ,
Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11, Schizophr. Bull. juill, vol.39, issue.4, pp.751-754, 2013. ,
The importance of measuring psychosocial functioning in schizophrenia, Ann. Gen. Psychiatry. 24 juin, vol.10, p.18, 2011. ,
Relation of C-reactive protein to abdominal adiposity, Am. J. Cardiol. 1 juill, vol.106, issue.1, pp.56-61, 2010. ,
Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset, Schizophr. Bull, vol.42, issue.5, pp.1290-302, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01482349
Catatonia. I. Rating scale and standardized examination, Acta Psychiatr. Scand. févr, vol.93, issue.2, pp.129-165, 1996. ,
, Acta Pharmacol. Toxicol. (Copenh.), vol.20, pp.140-144, 1963.
Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes, J. Neuropsychiatry Clin. Neurosci, vol.19, issue.4, pp.406-418, 2007. ,
Prediction of functional remission in first-episode psychosis: 12-month follow-up of the randomized-controlled trial on extended early intervention in Hong Kong, Schizophr. Res. mai, vol.173, issue.1-2, pp.79-83, 2016. ,
Obesity and C-reactive protein in various populations: a systematic review and meta-analysis, Obes. Rev. Off. J. Int. Assoc. Study Obes. mars, vol.14, issue.3, pp.232-276, 2013. ,
From inflammation to sickness and depression: when the immune system subjugates the brain, Nat. Rev. Neurosci. janv, vol.9, issue.1, pp.46-56, 2008. ,
Fetal programming of schizophrenia: Select mechanisms, Neurosci. Biobehav. Rev. févr, vol.49, pp.90-104, 2015. ,
, DSM-5 ®. : manuel diagnostique et statistique des troubles mentaux
The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance, Arch. Gen. Psychiatry. juin, vol.33, issue.6, pp.766-71, 1976. ,
High C-reactive protein levels are associated with depressive symptoms in schizophrenia, J. Affect. Disord, vol.01, pp.671-676, 2018. ,
Said NS. C-reactive protein serum level in drugfree male Egyptian patients with schizophrenia, Psychiatry Res, vol.190, issue.1, pp.91-98, 2011. ,
What does plasma CRP tell us about peripheral and central inflammation in depression?, Mol. Psychiatry [Internet], vol.12, 2018. ,
,
C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications, Mol. Psychiatry. avr, vol.21, issue.4, pp.554-64, 2016. ,
Measuring psychosocial outcomes in schizophrenia patients, Curr. Opin. Psychiatry. mars, vol.24, issue.2, pp.91-100, 2011. ,
Effect of Tobacco Smoking Cessation on C-Reactive Protein Levels in A Cohort of Low-Dose Computed Tomography Screening Participants, Sci. Rep. 27 août, vol.8, issue.1, pp.1-7, 2018. ,
Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res, vol.198, pp.212-217, 2012. ,
Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders, J. Am. Med. Assoc. 21 sept, vol.132, issue.3, p.126, 1946. ,
Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia, Neuroscience, vol.41, issue.1, pp.1-24, 1991. ,
ECDEU assessment manual for psychopharmacology by Guy, William; National Institute of Mental Health ,
Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults, Ann. Neurol. avr, vol.71, issue.4, pp.444-57, 2012. ,
Assessment of remission in schizophrenia with the CGI and CGI-SCH scales, Acta Psychiatr. Scand. févr, vol.117, issue.2, p.156, 2008. ,
Inflammatory Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study, JAMA Psychiatry. 1 déc, vol.74, issue.12, p.1226, 2017. ,
Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?, Schizophr. Bull. mars, vol.35, issue.2, pp.300-306, 2009. ,
Formes évolutives ; rémissions ; formes terminales, 1955. ,
Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis, Lancet Psychiatry, vol.4, issue.4, pp.295-301, 2017. ,
Predictive value of cognition for different domains of outcome in recent-onset schizophrenia, Psychiatry Res. 15 janv, vol.149, issue.1-3, pp.71-80, 2007. ,
Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia, Eur. Psychiatry J. Assoc. Eur. Psychiatr. août, vol.27, issue.6, pp.401-406, 2012. ,
The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation, Br. J. Psychiatry, issue.7, pp.59-67, 1989. ,
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment, Lancet Psychiatry. mars, vol.2, issue.3, pp.258-70, 2015. ,
Symptomatic and functional remission and its associations with quality of life in patients with psychotic disorder in Assertive Community Treatment teams, Compr. Psychiatry, vol.53, issue.8, pp.1174-80, 2012. ,
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later, Dialogues Clin. Neurosci, vol.12, issue.3, pp.393-407, 2010. ,
Time-stability of the « Functional Remission of General Schizophrenia » (FROGS) scale, Eur. Psychiatry J. Assoc. Eur. Psychiatr. août, vol.27, issue.6, pp.437-478, 2012. ,
Life expectancy and cardiovascular mortality in persons with schizophrenia, Curr. Opin. Psychiatry. mars, vol.25, issue.2, pp.83-91, 2012. ,
Excess early mortality in schizophrenia, Annu. Rev. Clin. Psychol, vol.10, pp.425-473, 2014. ,
A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors, Schizophr. Res. 15 juill, vol.76, issue.2-3, pp.135-57, 2005. ,
What does the PANSS mean?, Schizophr. Res, vol.15, issue.2-3, pp.231-239, 2005. ,
Inflammation and atherosclerosis, Circulation. 5 mars, vol.105, issue.9, pp.1135-1178, 2002. ,
Operational criteria and factors related to recovery from schizophrenia, Int. Rev. Psychiatry. janv, vol.14, issue.4, pp.256-72, 2002. ,
Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review, Schizophr. Bull, vol.33, issue.6, pp.1324-1366, 2007. ,
The « Functional Remission of General Schizophrenia » (FROGS) scale: development and validation of a new questionnaire, Schizophr. Res. sept, vol.113, issue.2-3, pp.218-243, 2009. ,
Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment, Prog. Neuropsychopharmacol. Biol. Psychiatry. août, vol.45, pp.92-101, 2013. ,
Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response, World J. Psychiatry. 22 juin, vol.5, issue.2, pp.182-92, 2015. ,
A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia, Schizophr. Res. janv, vol.170, issue.1, pp.1-17, 2016. ,
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III, Schizophr. Res. déc, vol.80, issue.1, pp.19-32, 2005. ,
A systematic review of longitudinal outcome studies of first-episode psychosis, Psychol. Med. oct, vol.36, issue.10, pp.1349-62, 2006. ,
Serum Creactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study, Brain. Behav. Immun. janv, vol.59, pp.253-262, 2017. ,
C-reactive protein levels in schizophrenia: a review and meta-analysis, Clin. Schizophr. Relat. Psychoses. janv, vol.7, issue.4, pp.223-253, 2014. ,
Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review, Schizophr. Res, vol.192, pp.16-29, 2018. ,
Neuroinflammation in schizophrenia especially focused on the role of microglia, Prog. Neuropsychopharmacol. Biol. Psychiatry. 5 avr, vol.42, pp.115-136, 2013. ,
Clinical effects of COX-2 inhibitors on cognition in schizophrenia, Eur. Arch. Psychiatry Clin. Neurosci. avr, vol.255, issue.2, pp.149-51, 2005. ,
The role of inflammation in schizophrenia, Front. Neurosci, vol.9, p.372, 2015. ,
Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge, Glia. févr, vol.64, issue.2, pp.300-316, 2016. ,
Standardized remission criteria in schizophrenia, Acta Psychiatr. Scand. févr, vol.113, issue.2, pp.91-96, 2006. ,
, Lancet Lond. Engl. 22 août, vol.374, issue.9690, pp.635-680, 2009.
Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation, Transl. Psychiatry. oct, vol.6, issue.10, pp.918-918, 2016. ,
Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection (PANDAS): Clinical Manifestations, IVIG Treatment Outcomes, Results from a Cohort of Italian Patients, Neuropsychiatry, issue.03, p.8, 2018. ,
Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the, American Heart Association. Circulation. 28 janv, vol.107, issue.3, pp.499-511, 2003. ,
Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis, Br. J. Psychiatry J. Ment. Sci. août, vol.205, issue.2, pp.88-94, 2014. ,
Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study, PLoS Med, vol.13, issue.6, p.1001976, 2016. ,
The Link Between the Immune System, Environment, and Psychosis, Schizophr. Bull. 1 juill, vol.43, issue.4, pp.693-700, 2017. ,
Complement in immune and inflammatory disorders: pathophysiological mechanisms, J. Immunol. Baltim. Md, vol.190, issue.8, pp.3831-3839, 1950. ,
Some aspects of the cost of schizophrenia in France, PharmacoEconomics. juin, vol.11, issue.6, pp.578-94, 1997. ,
A systematic review of the prevalence of schizophrenia, PLoS Med. mai, vol.2, issue.5, p.141, 2005. ,
Schizophrenia risk from complex variation of complement component 4, Nature. 11 févr, vol.530, issue.7589, pp.177-83, 2016. ,
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry, vol.14, pp.339-386, 2015. ,
Association between C-reactive protein and risk of schizophrenia: An updated meta-analysis, Oncotarget. 18 mai, vol.8, issue.43, pp.75445-54, 2017. ,
Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment, Eur. Arch. Psychiatry Clin. Neurosci. févr, vol.258, issue.1, pp.48-58, 2008. ,
Elevated C-reactive protein associated with late-and very-late-onset schizophrenia in the general population: a prospective study, Schizophr. Bull. sept, vol.40, issue.5, pp.1117-1144, 2014. ,
,
, Rémission symptomatique, n (%) 49 (18.6%) 31 (64.6%) 18 (8.4%)
,
, Comorbidités Obésité, p.69
,
, Fumeurs actifs réguliers, n (%), p.165
, Syndrome métabolique, n (%) 58 (22.1%) n (%) 105
, Les associations significatives (p < 0.05) sont en gras
, La rémission symptomatique a été définie selon les critères d'Andreasen. La présence du syndrome métabolique a été définie selon les critères de la Fédération Internationale du Diabète